This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): PEG-a-interferon-2a, Peginterferon alfa-2a, R442, RG442
Description: Pegasys is a covalent conjugate of recombinant alfa-2a interferon. Pegasys stimulates the production of effector proteins such as serum neopterin and 2',5'-oligoadenylate synthetase.
Revenue splits for this drug are BioMedTracker estimates.
Roche and Schering-Plough
In August 2001, Schering-Plough, pursuant to a cross-license agreement entered into as part of the settlement of certain patent lawsuits, granted Hoffmann-La Roche a sublicense under Enzon's branched PEG patents to allow Hoffmann-La Roche to make, use, and sell Pegasys.
Roche and Chugai
In December 2001, Roche Nippon and Chugai announced that they will merge. The Roche Group will become the majority shareholder of Chugai with a 50.1% interest. Chugai will be Roche's exclusive pharma representative in Japan and will have rights to develop and market all pharmaceutical products which the Roche Group decides to commercialize in Japan, including Pegasys.
In August 2014, Chugai announced that it has amended the business arrangements with F. Hoffmann-La Roche Ltd. regarding the terms and conditions for out-licensing Chugai products based on the strategic alliance...See full deal structure in Biomedtracker
Partners: Nektar Therapeutics Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: